GlobeNewswire Inc.··Celcuity Inc.Celcuity's Gedatolisib Shows 76% Risk Reduction in Breast Cancer Trial
Celcuity's gedatolisib achieved 76% risk reduction in advanced breast cancer with PIK3CA wild-type mutations; FDA Priority Review decision expected July 2026.
CELCPhase 3 trialprogression-free survival